In a landmark step for addiction treatment, Awakn Life Sciences Corp. has received the green light to commence Phase III clinical trials for its pioneering treatment, AWKN-P001, targeting Severe Alcohol Use Disorder (SAUD).

Psychedelic research is expanding, as scientists push the boundaries of scientific discovery and delve into the untapped potential of psychedelic substances. Let's explore some of the latest developments that are revolutionizing our understanding of psychedelics and their implications for scientific breakthroughs.